A method for the identification and quantification of the antiepileptics lamotrigine, Carbamazepine and Carbamazepine epoxide (active metabolite) in human serum is described. In refractory epilepsy the combination of Carbamazepine and lamotrigine was recently developed to a modern therapeutic concept. The goal of this paper is therapeutic drug monitoring (TDM) of these substances. Serum was extracted with a quick precipitation method using a modified commercial extraction-kit and analysed by gas chromatography mass Spectrometry (GC-MS). A gas-chromatographic temperature-pressure programme was developed that allowed the determination of lamotrigine by gas chromatography mass Spectrometry. A reference spectrum of pure lamotrigine is herewith published for the first time. A new mass spectra library was created to support the identification of the antiepileptics in human serum. In the Specified Ions Monitoring mode (SIM) a detection limit below the therapeutic range and recoveries above 90% were obtained.
Introduction
In this paper we describe the development of a new GCLamotrigine is a new antiepileptic drug and has recently MS method ' combined with a modified commercially shown promise in add-on therapy with other antiepilepavailable HPLC extraction ^ which S ave us the P ossi -tic drugs in refractory epilepsy and for resistant partial bil^ to determine lamotrigine together with carbarn-/1X azepine and Carbamazepine epoxide in blood during seizures (1) . r ±-r o add-on therapy in one analytical run. Therapeutic drug monitoring of antiepileptics can help to optimize therapeutic efficiency and patient safety. The relationship between the concentration of lamotrigine and Materials and Methods other antiepileptic drugs in plasma and their therapeutic ef-Reagents feet has been described in many studies (1) (2) (3) . Serum con-Carbamazepine was obtained from Abbott Diagnostics (Wiesbaden, centrations in responding patients receiving chronic treat-Sf" ° (Deisenhofen, Germany), lamotngine was purchased from Wellment with lamotrigine and exhibiting therapeutic effects com e (Wedel, Germany) and drug-free serum from Bio-Rad were seen to be 0.9-1.8 mg/1 (4), in practice a therapeutic Laboratories (Munich, Germany). Carbamazepine epoxide was a gift range from 0.5-4.5 mg/1 was found (5 by therapeutic drug monitoring. In the early nineties HPLC mochem Gm bH (Wesel, Germany). and immunoassay determinations of lamotrigine in serum A11 . , , , ,. , 1An " " , , . 4 . lx , 3 6 All standard solutions (1000 mg/1 solved in methanol) were stored were described (6) (7) (8) . However, only HPLC assays have a t -70 °C until use, for shorter times (some weeks) storage at been commercially available up to now.
-20 °c seems sufficient.
_ Instrumentation ') Preliminary results were presented as poster at the IFCC con-A Hewlett Packard 5972 Mass Spectrometer combined with a gress in London 1996 (Proc XVI ICCC 1996, 114).
Hewlett Packard 5890 series II plus gas Chromatograph was used. It was equipped with a split-splitless injector and a capillary column DB-5ht (length 30 m, I. D. 0.250 mm, film 0.100 μηι) from J&W Scientific (ICT, Bad Homburg, Germany).
The gas Chromatographie conditions were: injection temperature 250 °C; transferline heater temperature 325 °C; helium flow-rate 0.815ml/min; injection volume: 2 μΐ splitless. The temperature programme started at 60 °C, this was held for 2 minutes, within 1 min the temperature was increased to 120 °C and held another 2 min, then the temperature was increased by 20 °C per min and held finally for l min at 25 °C. In the SIM-mode the same conditions were used, except that 400 EMV were added. The selected masses for identification and quantification and the ion-group-start time were as shown in table 1.
Carbamazepine was also measured by FPIA using the TDx /FLx analyzer from Abbott (Wiesbaden, Germany). Lamotrigine was additionally measured by reversed phase HPLC. Thereby the same extraction procedure and a commercially available isocratic HPLC method with UV-detection from Recipe (Kit No. 15100) were used.
Samples, tubes, storage
Blood was taken in 4.5 ml Vacutainer® serum separator tubes (Beeton Dickinson, Heidelberg, Germany). Serum was stored at 4 °C, for periods up to 7 days at -70 °C.
Procedures

Extraction of antiepileptics
In principle a combination of precipitation and liquid extraction was used. Serum (0.1 ml) and 0.15 ml precipitation reagent (acetonitril containing imipramine 5 mg/1 as internal standard) were added to the prepared extraction vials. After vortexing for 30 s and centrifugation (5 min at 10000 g) 0.1 ml of the organic supernatant was evaporated to dryness with Na at room temperature and the residue dissolved in 50 μΐ ethylacetate.
Identification of antiepileptic drugs
As peak integrator the Chem-Station-Integrator from Hewlett Packard was used. Critical conditions were adjusted to: initial area reject activated, initial peak width 0.020, shoulder detection off, initial threshold 8.
The conditions for library-search-strategy were: prefilter-control (U-A) adjusted to 3, tilting to off, crosscorrelation to off, minimum estimated purity 50%. A library of mass-spectra, prepared by us, was used for the identification of antiepileptics. It contained adapted spectra from PMW TOX2 Mass Spectral Database (9) or NIST/EPA/NIH Mass Spectral Database (Hewlett Packard Company, Palo Alto, CA) as well as spectra of pure substances examined by us in the SCAN and SIM modes. The mass spectrum of lamotrigine was recorded for the first time in our laboratory and verified with a sector field mass spectrometer at the pharmaceutical faculty of Ludwig Maximilians University (Munich, Germany). For probabilities greater than 65% we searched the Pfleger-Maurer (9) library. If this was not successful, we changed automatically to the library we created. This enabled us in the scan-mode to recognize other drugs in addition. No gas-chromatographic interferences with the antiepileptics were detected. In the SIM-mode we only used our own library.
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Quantification of antiepileptic drugs
We used the dominant mass of each antiepileptic drug and the selected internal standard for quantification (tab. 2). The calibration for carbamazepine epoxide, carbamazepine and lamotrigine was obtained from six drug free serum samples containing 0; 0.625; 1.25; 2.5; 5.0; 10.0; 20.0 mg/1 of these drugs. Imipramine was used as internal standard.
Results and Discussion
Identification and quantification of antiepileptic drugs
Lamotrigine and carbamazepine were extracted from spiked serum (concentration of lamotrigine was 50 mg/1, of carbamazepine 6 mg/1) and separated by GC-MS. In the total ion chromatogram individual peaks were obtained ( fig. 1 ). The extraction procedure of the manufacturer for HPLC analysis was changed by drying and redissolving the eluate in pure ethylacetate. This resulted in a clean extract and gave high recoveries of the antiepileptic drugs. The insert in figure 1 shows the mass spectrum of lamotrigine. The dominant fragment mass(es) of each substance were selected for quantification (SIM-mode). Due to the low Chromatographie response of lamotrogine the signals of three masses (tab. 2) were used after summation. Figure 2 shows a chromatogram of lamotrigine, carbamazepine epoxide and carbamazepine in the SIM-mode together with the internal standard imipramine. With this procedure the detection limits (tab. 2) were found to be beyond the therapeutic levels (4, 5).
Typical calibration curves are given in figure 3 . For all compounds an excellent correlation was found between standard amount and signal (tab. 3). In addition, this table shows the intraassay precision data of our quantification method. CV's were found between 3 and 12%. Accuracy could not be tested with quality control materials (lacking target values for GC-MS), but was determined with spiked serum samples. Analysis of 10 to 30 (for lamotrigine) spiked serum samples showed analytical recoveries between 90 and 111% for all drugs.
Assay correlation
The results obtained with GC-MS and immunoassay (for carbamazepine) or HPLC (for lamotrigine) were compared using the Passing-Bablok method. The correlation coefficients (r 2 ) were higher than 0.95 and the regression lines obtained for carbamazepine and lamotrigine are shown in figure 4 a and b. Only two results for lamotrigine disagreed by more than 10%. The results obtained by GC-MS were repeatedly higher. The nature of the differences could not be explained, particularly, no such differences were seen with stock samples. 
Conclusion
Therapeutic drug monitoring of antiepileptic drugs is mainly achieved by immunoassays because these methods can be mechanized and are computerized. For lamotrigine, however, determination by immunoassay, although described in the literature (7, 8) , is presently not commercially available. In recent years several HPLC methods for quantitation of lamotrigine have been published (6) . The present GC-MS method, however, has not been described before. The GC-MS method presented in this paper seems to be advantageous for measurements of samples from patients on an add-on therapy of lamotrigine with other antiepileptic drugs.
The application of GC-MS is supported by the availability of a simple, effective and reproducible sample preparation procedure. As experienced with various extraction procedures (10) , the use of a modified commercial extraction kit (see procedures) gave a clean extract with good recovery and precision. Although this step is not necessary for immunoassay, it opens the possibility to determine coadministered antiepileptic and other drugs from the same extract. Together with the advantages provided by GC-MS, which are achieved by correlation of two properties (retention time and mass spectrum), a high certainty of identification is given. This is especially the case when using 5 fragment masses in the Under practical aspects GC-MS seems today to be superior to HPLC because the detection limit (not only signal to noise ratio) is lower and no change of the column or solvent is necessary, if another group of compounds has to be analysed. Therefore the GC-MS equipment can be used in one sequence (without technical changes) for confirmation of screening results in drug abuse testing, for general unknown screening, and e. g. for therapeutic drug monitoring. This variability cannot be achieved with HPLC. Laboratories with low sample input should consider this if they want to establish a Chromatographie technique.
